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pletion studies. They conﬁrm the profound effect of storage on
alloimmunization in this clear-cut model but also observe that NLRP3/
caspase-1 is not required for the effect (Gibb et al., 2016).
While these data reject a relevant hypothesis that NLRP/caspase-1 is
required (e.g. negative data), they do not reject a potential involvement
of NLRP/caspase-1, due to the potential for redundant pathways thatIt is generally more difﬁcult to publish negative than positive scien-
tiﬁc data, although everyone acknowledges how useful negative ﬁnd-
ings can be. This issue of EBioMedicine presents such negative results
that are nevertheless valuable. Gibb et al. (Gibb et al., 2016) have ad-
dressed the question of the intracellular machinery pertaining to in-
ﬂammation and its potential role in regulating alloimmunization to
red blood cell (RBC) antigens. Gibb et al. attempted to test the role of
mobilizing the inﬂammasome of innate immune cells in an experimen-
tal (mouse) model of alloimmunization. They sought to model real-life
conditions of transfusion by providing stored RBC components
(RBCCs). RBCC storage was previously shown to increase
alloimmunization in the mouse, a model which simpliﬁes the
alloantigenic barriers. The relevance of old vs fresh RBCCs in humans
is not yet ascertained with respect to medical outcomes (Martí-
Carvajal et al., 2015), though there is common sense evidence that
fresh cells may do better than old ones (Eikelboom et al., 2016). Studies
investigating the effect of RBC storage time on alloimmunization in
humans have given conﬂicting results, with a clear association observed
in some settings, but no association in others.
In the current report, the authors hypothesized that damage-associ-
ated molecular patterns (DAMPs) share responsibility in inducing in-
ﬂammation and subsequent alloimmunization. Storage for a limited
period of time is indeed necessary to generate a safe blood component
(BC) inventory, although it also results in the storage lesion (Delobel
et al., 2016). To investigate their hypothesis, Gibb et al. focused on a
major inﬂammasome molecule i.e. NLRP3, which is a member of the
NOD-like receptor family that activates caspase-1 and triggers the re-
lease of IL-1β and IL-18. Both of these pro-inﬂammatory cytokines fuel
the inﬂammation linked-process of antigen presentation and the epi-
tope speciﬁc T lymphocyte response to antigen presenting cells
(APCs). The authors have used well-characterized inﬂammasome KOom.2016.06.008.
. This is an open access article undermice, and elegantly proceededwith conventional dendritic cell (DC) de-
may rescue the phenomenon even if a major pathways is eliminated.
It has to be understood that redundant pathways are natural safety
measures, and are thus likely to be present in many systems.
Transfusion (and pregnancy)-induced immunization to blood cell
antigens is the ﬁrst adverse event after transfusion of cellular BCs,
with frequency varying from 0.1% to 10% depending on the cohorts,
the transfusion operation system and the hemovigilance and reporting
system. In humans, because of the multiplicity of genetically indepen-
dent blood group antigens, perfectmatches between BCs' and the recip-
ients' phenotypes are not practically possible. Alloimmunizationmay be
extremely serious when patients present with pathologies requiring
chronic transfusion, such as thalassemia major and sickle cell disease.
It is estimated that even in settings where blood components are pre-
storage leukoreduced to less than 106 residual cells, nearly 10% of sickle
cell disease patients become immunized to RBC antigens other than
RH:1 (D) antigen (Semple, 2004) (and nearly 30–50% when BCs are
not leukoreduced). The cumulative production of multiple alloanti-
bodies can render the recipient refractory to transfusion.
Despite these rates of alloimmunization, the vastmajority of transfu-
sion is tolerated in a manner such that no signiﬁcant alloantibody is
formed that compromises subsequent transfusion or complicates preg-
nancy. Immunological reasons for variant responses to antigen mis-
matched blood cells are not well understood. They are comprised of
factors linked with: -i) donor characteristics (antigens vary in immuno-
genicity); -ii) BC characteristics (prestorage, leukoreduction, age of
blood, plasma mitigation, Transfusion Immuno Modulation (TRIM)-re-
lated factors); -iii) recipients characteristics (genetic susceptibility,
causal disease, associated treatment, and immunomodulatory or immu-
nosuppressant drugs).
For several decades, alloimmunization has been ascribed solely to
the immunogenicity of BC antigens. It was then acknowledged that sys-
tematic, prestorage, and stringent leukoreduction signiﬁcantly reduce
the frequency of alloimmunization (Semple, 2004). Meanwhile, inter-
esting studies from experimental mouse systems indicated thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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alloimmunization, suggesting some room for TRIM (Pavenski et al.,
2012). The beneﬁcial effect of leukoreduction on alloimmunization
sheds light on the so-called indirect presentation by professional APCs
to recipients' T-lymphocytes (Pavenski et al., 2012). Later still, a new
paradigm in alloimmunization has been recognized. Immunized pa-
tients were no longer ascribed a status of “good responders” but rather
as “good presenters”, as their HLA receptors preferentially present cer-
tain blood group antigen epitopes (Körmöczi andMayr, 2014): as amat-
ter of fact, this is an unfortunate selective (dis)advantage as compared
to being a “good presenter” of infectious pathogen derived epitopes.
This is a case of direct presentation (recipients' APCs present to their
own T-lymphocytes). Data has now accumulated showing that inﬂam-
mation is central to (allo)immunization (Hod, 2015); inﬂammation al-
lows the recruitment of APCs, the creation of a cytokine/chemokine
milieu (alongwith the activation of other Biological ResponseModiﬁers
[BRMs]). Pro-inﬂammatory BRMs are seminal to the success of antigen
presentation, the dampening of tolerance, and the rescue of reactive
T-lymphocyte apoptosis (Pietrosimone and Liu, 2015). Inﬂammation
can be viewed as the consequence of the activation of innate immune
cells detecting a series of danger signals through surface pattern-recog-
nition receptors (PRRs) detectingDAMPs on allogeneic blood cells. Once
activated, these sensors activate intracellular pathways that end up reg-
ulating gene expression; as a consequence, the cell sensor secretes spe-
ciﬁc pattern of BRMs (Pietrosimone and Liu, 2015).
Beyond providing insights allowing better handling of chronically
anemic patients, one can contemplate the capacity of Nature to use
tricks to distract external attempts to dampen alloimmunization. Trans-
fusionwith homologous BCs is unnatural and is sensed as foreignmate-
rial and perceived as potentially dangerous by the innate immune
system: such a response is indeed derived from a set of safety measurespresent in the immune system to protect the body against foreign path-
ogens. This also indicates that measures to dampen the system may be
sought—that would ideally “distract the distractors”, despite a likely dif-
ﬁculty in achieving this task.Disclosure
The author declared no conﬂicts of interest.References
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